Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

AbCellera Biologics Inc. Common Shares (ABCL)

NASDAQ: ABCL · Pharmaceutical Preparations · Vancouver, A1

Our rating: Cautious

Cautious reaffirmed at $12.46, moderate conviction, November 10, 2026.

Breaks if: The Cautious view is wrong if the next two quarterly filings (through mid-2027) each show free-cash-flow burn below $35M while year-over-year revenue growth holds above 80% — that combination would indicate the platform is converting partnerships to cash without proportional capital drag, making the current revenue multiple more defensible and warranting a move to Neutral. A stock that climbs and holds above $16.50 within twelve months would similarly indicate the market is seeing milestone conversion not visible in today's figures.

Key figures

Market value$3.2B
Revenue, last 12 months$68M
Net income, last 12 months−$148M
Free cash flow, last 12 months−$33M
Price to earningsn/a
Free cash flow yield−1.0%
Dividend yield0.0%
Operating margin−298.0%
Return on equity−14.6%
Beta to the S&P 5001.70
Volatility, annualized77.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$11M18.8%$-0.13$25M
June 30, 2026$4M−76.3%$-0.18$24M
March 31, 2026$8M96.3%$-0.14−$37M
December 31, 2025$45M788.2%$-0.03−$45M
September 30, 2025$9M37.6%$-0.19−$62M
June 30, 2025$17M133.3%$-0.12−$46M
March 31, 2025$4M−57.5%$-0.15−$22M
December 31, 2024$5M−45.0%$-0.11−$24M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

32 ledger entries and 10 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.